Antithrombotic amongst NICE technology appraisals for July

Bivalirudin, intravitreal dexamethasone and retigabine have been appraised by NICE | SCIENCE PHOTO LIBRARY
Bivalirudin, intravitreal dexamethasone and retigabine have been appraised by NICE | SCIENCE PHOTO LIBRARY
The technology appraisals issued by NICE in July included an antiepileptic, an antithrombotic and an intravitreal implant.

Bivalirudin in combination with aspirin and clopidogrel has been recommended for the treatment of patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Dexamethasone intravitreal implants have been approved for the treatment of macular oedema secondary to central retinal vein occlusion. It is also recommended for macular oedema following branch retinal vein occlusion when treatment with laser photocoagulation:
•    has not been beneficial or
•    is considered unsuitable owing to the extent of macular haemorrhage.

Retigabine has been recommended by NICE as an option for the adjunctive treatment of partial onset seizures with or without secondary generalisation in adults with epilepsy, only when previous treatment with carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate and topiramate has not provided an adequate response or has not been tolerated.


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Removed: Xepin.
Use our constantly updated shortages...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests